WASHINGTON — President Trump’s government order to decrease drug costs by way of sweeping, cross-agency motion left leaders within the pharmaceutical business scrambling Monday to make sense of what could also be forward — and methods to reply.
The announcement was lengthy on messaging, however quick on particulars. That will clarify why share costs for a lot of pharmaceutical and biotech corporations dropped within the hours earlier than the announcement, however gained floor after traders took inventory of Trump’s strikes.
“This has the texture of a Fact Social submit within the type of an government order,” stated Brian Reid of Reid Strategic, a marketing consultant who works with drug corporations on pricing and entry points. “It’s a bully pulpit transfer. There’s no precise directions on methods to use the legislation to effectuate this. It’s merely a press release that he needs costs to be decrease.”
This text is unique to STAT+ subscribers
Unlock this text — plus day by day intelligence on Capitol Hill and the life sciences business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
